The Audited Financial Results (Standalone and consolidated) of the Company for the last quarter and year ended March 31, 2025 and Audited Annual Accounts of the Company the quarter and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.6 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Remedium Lifecare Ltd held its board meeting on May 30, 2025, and approved the audited consolidated and standalone financial results for Q4 and the full year ended March 31, 2025. Consolidated total income for FY25 stood at Rs 41,605.37 lakh, with profit after tax of Rs 212.94 lakh (EPS Rs 0.05). However, Q4 FY25 alone showed a loss after tax of Rs 204.60 lakh (EPS Rs -0.05) on revenue of Rs 26,432.27 lakh. The statutory auditor (Taori Sandeep & Associates) issued an unmodified opinion on both standalone and consolidated results. Networth marginally dipped from Rs 4,329.51 lakh to Rs 4,295.78 lakh, with no outstanding qualified borrowings. The board also appointed Ms Riddhi Shah as Secretarial Auditor for 5 years (FY26–FY30), two new Independent Directors (Mr Bikram Kumar Mund and Mr Vijay Pal Singh Gulya), and Mr Kapil Goplani as Company Secretary cum Compliance Officer effective June 1, 2025.
The annual numbers show profitability, but the Q4 standalone loss and dip in networth are minor concerns. Multiple governance additions (auditor, two independent directors, CS) signal board strengthening rather than distress. Shareholders should watch for sustained quarterly performance trends.